- Direction
- Deteriorating
- Own history
- 50th
- Peers
- 67th
- Persistence
- EMERGING
· Services-Commercial Physical & Biological Research
RESEARCH SNAPSHOTINCYTE CORP's latest supported as-filed period reports revenue of $1.6B. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -43.37% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 14.00% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 8.62% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 93.02% · CORE
Level · gp.fundamentals.operating_margin
Raw value -45.49% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 115.06% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 4.48% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Inventory increased 60.9%; Inventory / revenue moved 251 bp higher.
2 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 14.0%; Operating margin moved 7796 bp lower; Operating income changed across a sign change.
3 evidence-backed componentsInventory changed +60.9% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
INCY · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0000879169-26-000066SEC ↗8-KOct 29, 2026Period Oct 29, 20260000879169-26-000063SEC ↗4Oct 19, 2026Period Oct 15, 20260001205703-26-000032SEC ↗4Oct 5, 2026Period Oct 1, 20260002039219-26-000010SEC ↗4Oct 2, 2026Period Sep 30, 20260001193125-26-412653SEC ↗4Oct 2, 2026Period Sep 30, 20260001409601-26-000015SEC ↗4Oct 2, 2026Period Sep 30, 20260001177917-26-000014SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Oct 15, 2026Filed Oct 19, 2026 | CAGNONI PABLO JPresident, Global Head of R&D | Option ExerciseDirect | 839 | $72 | $60,349 | Form 4 ↗ |
| Oct 15, 2026Filed Oct 19, 2026 | CAGNONI PABLO JPresident, Global Head of R&D | Option ExerciseDirect | 423 | $62 | $26,124 | Form 4 ↗ |
| Oct 15, 2026Filed Oct 19, 2026 | CAGNONI PABLO JPresident, Global Head of R&D | Option ExerciseDirect | 455 | $61 | $27,837 | Form 4 ↗ |
| Oct 15, 2026Filed Oct 19, 2026 | CAGNONI PABLO JPresident, Global Head of R&D | Option ExerciseDirect | 925 | $64 | $59,431 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating margin changed -7796 basis points from the comparable as-filed period.
Cash & equivalents changed +33.4% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Research & development changed +253.7% from the comparable as-filed period.
Working capital changed +38.9% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Current assets changed +29.1% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Shares outstanding changed +3.8% from the comparable as-filed period. The change ranks at the 88th percentile of 8 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-09-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0002085970-26-000007| Oct 15, 2026Filed Oct 19, 2026 |
| CAGNONI PABLO JPresident, Global Head of R&D |
| Open Market SaleDirect |
| 2,642 |
| $113 |
| $297,780 |
| Form 4 ↗ |
| Oct 15, 2026Filed Oct 19, 2026 | CAGNONI PABLO JPresident, Global Head of R&D | Option ExerciseDirect | 839 | $0 | $0 | Form 4 ↗ |
| Oct 15, 2026Filed Oct 19, 2026 | CAGNONI PABLO JPresident, Global Head of R&D | Option ExerciseDirect | 423 | $0 | $0 | Form 4 ↗ |
| Oct 15, 2026Filed Oct 19, 2026 | CAGNONI PABLO JPresident, Global Head of R&D | Option ExerciseDirect | 455 | $0 | $0 | Form 4 ↗ |
| Oct 15, 2026Filed Oct 19, 2026 | CAGNONI PABLO JPresident, Global Head of R&D | Option ExerciseDirect | 925 | $0 | $0 | Form 4 ↗ |
| Oct 1, 2026Filed Oct 5, 2026 | Heeson LeeEVP, Head of Incyte Intl | Tax WithholdingDirect | 463 | $117 | $54,236 | Form 4 ↗ |
| Sep 30, 2026Filed Oct 2, 2026 | Clancy Paul JDirector | Grant Or AwardDirect | 203 | $121 | $24,634 | Form 4 ↗ |
| Sep 22, 2026Filed Sep 24, 2026 | Gardner David HEVP, Chief Strategy Officer | Tax WithholdingDirect | 920 | $127 | $116,776 | Form 4 ↗ |
| Sep 15, 2026Filed Sep 17, 2026 | CAGNONI PABLO JPresident, Global Head of R&D | Option ExerciseDirect | 2,957 | $62 | $182,624 | Form 4 ↗ |
| Sep 15, 2026Filed Sep 17, 2026 | CAGNONI PABLO JPresident, Global Head of R&D | Option ExerciseDirect | 4,551 | $61 | $278,430 | Form 4 ↗ |
| Sep 15, 2026Filed Sep 17, 2026 | CAGNONI PABLO JPresident, Global Head of R&D | Option ExerciseDirect | 6,477 | $64 | $416,147 | Form 4 ↗ |
| Sep 15, 2026Filed Sep 17, 2026 | CAGNONI PABLO JPresident, Global Head of R&D | Option ExerciseDirect | 9,233 | $72 | $664,130 | Form 4 ↗ |
| Sep 15, 2026Filed Sep 17, 2026 | CAGNONI PABLO JPresident, Global Head of R&D | Open Market SaleDirect | 9,233 | $121 | $1.1M | Form 4 ↗ |
| Sep 15, 2026Filed Sep 17, 2026 | CAGNONI PABLO JPresident, Global Head of R&D | Open Market SaleDirect | 13,985 | $120 | $1.7M | Form 4 ↗ |
| Sep 15, 2026Filed Sep 17, 2026 | CAGNONI PABLO JPresident, Global Head of R&D | Option ExerciseDirect | 2,957 | $0 | $0 | Form 4 ↗ |
| Sep 15, 2026Filed Sep 17, 2026 | CAGNONI PABLO JPresident, Global Head of R&D | Option ExerciseDirect | 4,551 | $0 | $0 | Form 4 ↗ |